上海翱路生物医药科技

Alloray Biopharmaceutical is a clinical-stage biotechnology company focused on the development of innovative radiopharmaceuticals for oncology. Headquartered in Shanghai, the company specializes in targeted alpha therapy (TAT), utilizing high-energy alpha-emitting isotopes to deliver precise radiation to cancer cells while minimizing damage to healthy tissue. Their pipeline includes candidates targeting prostate-specific membrane antigen (PSMA) and fibroblast activation protein (FAP) for the treatment of prostate cancer and various solid tumors. Alloray integrates ligand discovery, isotope supply chain management, and specialized manufacturing to accelerate the delivery of next-generation nuclear medicines. The company is backed by prominent investors including Sequoia China and GL Ventures.